Olokizumab  (Synonyms: 奥洛组单抗; CDP 6038; OKZ)

Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6). Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Olokizumab (从 10 µg/mL 开始；72 h) 可抑制原代人肝细胞中的急性期蛋白产生，表明其中和 IL-6 顺式信号传导^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Olokizumab (1-20 mg/kg；静脉注射；每周一次) 显著降低胶原诱发的关节炎食蟹猴模型中关节炎评分、CRP 水平，并改善组织学和骨侵蚀评分^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

3569  [NCBI]

P05231

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.94 kDa

1007223-17-7

液体

Colorless to light yellow

奥洛组单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Kretsos K, et, al. Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 18;3(6):e119.  [Content Brief]

  [2]. Shaw S, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82.  [Content Brief]

  [3]. Tavakolpour S. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors & Clinical Investigation, 2016, 3.